Offer teenagers a meningitis B vaccine on NHS, advisers tell UK government
UK vaccine advisers JCVI recommend that teenagers around age 15 be offered the meningitis B vaccine on the NHS, with catch-up jabs for those who missed it as babies, following deadly outbreaks.
Intelligence analysis by Llama
The Joint Committee on Vaccination and Immunisation (JCVI) has told the UK government to extend NHS meningitis B vaccination to teenagers around age 15, with catch-up doses for older children who were never offered the infant jab. The recommendation, triggered in part by a Kent outbreak that killed two young people, still needs government sign-off.
Some experts who advise the UK government say teenagers should get a meningitis B jab around age 15, because young people heading to college or university are more likely to catch the disease. Babies already get the vaccine, so this would add a top-up shot for teens, plus a chance for older kids who missed it as babies to get protected too.
Analysis
From Kent's Tragedy to a National Recommendation
The JCVI's recommendation lands in the shadow of a specific and painful episode. Earlier in 2026, an outbreak of meningitis B at the University of Kent left two teenagers dead, including 18-year-old Juliette Kenny, whose family has since been campaigning for routine access to the vaccine for young people. According to the article, the JCVI framed its adolescent recommendation around the principle of protecting teenagers at the point they are next most at risk — typically the university and college years — rather than relying solely on infant immunisation introduced a decade earlier.
The data underpinning the move is unusually encouraging. The article notes that evidence suggests the menB vaccine is highly effective, providing strong protection for at least five years after vaccination, which gives the proposed age-15 window a credible immunological rationale. That is also why the committee is recommending a single booster for those who had the infant jab and two doses for those who did not.
A Two-Tier Plan for a One-Disease Problem
The committee's structure is worth unpacking. Children born on or after 1 May 2015 were already eligible for the menB jab as babies, so the JCVI is recommending a booster around age 15 to bridge into the high-risk teenage window — with the first cohort set to turn 15 in 2030. Children born on or before 31 April 2015, by contrast, never had access to the infant programme, and the JCVI "strongly supports" giving them two doses as teenagers to compensate.
Crucially, the JCVI's role ends at recommendation. The article makes clear that the Department of Health will consider the advice, and that each of the UK's four nations would decide for itself whether the cost of a catch-up programme is justified. That devolved decision-making has historically produced uneven vaccine rollouts across the UK, and it is the most likely source of delay or divergence here.
A Summer Lifeline and an Autumn Choice
The adolescent recommendation sits alongside, but is separate from, an already-announced summer programme covering roughly a million Year 13 pupils and under-25s heading into university or further residential education this autumn. Prof Wei Shen Lim, the JCVI chair, is quoted urging eligible young people to book appointments at local pharmacies, stressing that two doses at least 28 days apart are required for protection. That summer scheme is, in effect, a stopgap; the new recommendation, if adopted, would make such catch-up efforts the norm rather than an emergency measure.
For the government, the decision is as much fiscal as clinical. The JCVI has signalled the clinical case is strong, and the political momentum — generated by bereaved families and a high-profile outbreak — is on the side of action. The risk of inaction is equally clear: another university outbreak on the scale of Kent's would be politically difficult to defend when advisers had already mapped out a workable response.
Key points
- JCVI recommends offering the menB vaccine to teenagers around age 15, with a booster for those vaccinated as infants and two doses for those who were not.
- First cohort eligible for the booster would turn 15 in 2030; children born on or before 31 April 2015 would be offered two doses under a catch-up element.
- Each UK nation would decide independently whether to fund a catch-up programme, meaning uneven rollouts are possible.
- Recommendation follows a Kent outbreak earlier in 2026 that killed two teenagers, including 18-year-old Juliette Kenny.
- Existing summer programme offering menB jabs to about a million Year 13 pupils and new university students remains in place.
- JCVI chair Prof Wei Shen Lim says the vaccine provides strong protection for at least five years after vaccination.
If the government accepts the recommendation, the UK would close a long-standing gap in meningitis B protection and likely see fewer of the university-cluster outbreaks that have marked recent years. Routine adolescent coverage would also spare future families the kind of loss suffered by the Kent victim's family.
The recommendation is non-binding and the cost of a catch-up programme is left to each UK nation to weigh, so uptake could be patchy and slow. With the first booster cohort not turning 15 until 2030, there is a long window in which universities remain exposed to the kind of outbreak seen in Kent.
